KDR and neoplasm: Early in 2013, it was found that combining anti-PD-1 monoclonal antibody and anti-VEGFR2 monoclonal antibody had a synergistic anti-tumor effect in a murine model with colon adenocarcinoma, suggesting that it might be an effective strategy in clinical practice [46].